Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2335 • 2019 ACR/ARP Annual Meeting
Prediction of Myocardial Fibrosis in Rheumatoid Arthritis Assessed by Cardiac Magnetic Resonance Imaging Using Artificial Neural Networks Models
Hitomi Kobayashi¹, Isamu Yokoe ², Yasuyuki Kobayashi ³, Eichi Takaya ⁴, Atsuma Nishiwaki ¹, Kaita Sugiyama ¹, Noboru Kitamura ¹, Masaki Haraoka ³ and Masami Takei ¹, ¹Nihon University School of Medicine, Tokyo, Japan, ²Kyoundo Hospital, Tokyo, Japan, ³St.Marianna University School of Medicine, Kawasaki, Japan, ⁴Graduate School, Keio University, Tokyo, Japan
Background/Purpose: Cardiac involvements cause of morbidity and mortality globally in rheumatoid arthritis (RA). Myocardial dysfunction may arise from a number of distinct processes, including myocardial…
Abstract Number: 2359 • 2019 ACR/ARP Annual Meeting
High Body Mass Index Shortens Retention of Tumor Necrosis Factor-α Blocker Treatment in Rheumatoid Arthritis
Ori Elkayam ¹, Merav Lidar ², Tatiana Reitblat ³, Devy Zisman ⁴, Alexandra Balbir-Gurman ⁵, Odelia Kakakian ¹, Tanya Meshiach ⁵, Ronit Almog ⁶ and Ofir Elalouf¹, ¹Tel Aviv Medical Center, Tel Aviv, Israel, ²Rheumatology Unit Sheba Medical Center, Ramat Gan, Israel, ³Barzilai Medical Center, Ashkelon, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Rambam Medical Center, Haifa, Israel, ⁶the7Epidemiology and Biostatistics Unit, Rambam Health Care Campus, Haifa, Israel
Background/Purpose: The primary objective was to evaluate the effect of body mass index (BMI) on tumor necrosis factor α (TNF-α) blockers (including etanercept, infliximab, adalimumab…
Abstract Number: 2386 • 2019 ACR/ARP Annual Meeting
Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Jesus Tornero¹, Mercedes Alperi-López ², Ivan Castellvi ³, Juan José de Agustín de Oro ⁴, Alejandro Escudero ⁵, Rosario Garcia-Vicuña ⁶, Miguel Angel González-Gay ⁷, Cristina Hidalgo ⁸, Esteban Rubio ⁹, Raimon Sanmarti ¹⁰, Núria Casamira ¹¹ and Jaime Calvo-Alen ¹², ¹Hospital de Guadalajara, Guadalajara, Spain, ²Hospital Universitario Central de Asturias, Oviedo, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁶Hospital Universitario de La Princesa, Madrid, Spain, ⁷Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁸Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ⁹Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, ¹⁰Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ¹¹Medical Department, Gebro Pharma S.A., Barcelona, Spain, ¹²Hospital Universitario Araba, Vitoria-Gasteiz, Spain
Background/Purpose: Our aim was to develop recommendations for the management of methotrexate (MTX) when considering the combination with biological (b) or targeted synthetic (ts) disease…
Abstract Number: 2764 • 2019 ACR/ARP Annual Meeting
Medication Necessity and Concerns Beliefs Are Distinct, Interactive Predictors of Treatment Adherence in Rheumatoid Arthritis
George Karpouzas¹, Elizabeth Hernandez ², Lorena Ruiz ³, Vibeke Strand ⁴ and Sarah Ormseth ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA, ³Harbor-UCLA andLos Angeles Biomedical Research Institute, Torrance, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Medication adherence is instrumental for the successful management of rheumatoid arthritis (RA) to a goal of remission. Awareness of medication necessity and concerns regarding…
Abstract Number: 2858 • 2019 ACR/ARP Annual Meeting
The Role of Bradykinin Receptor B1 and Its New Ligand Soluble CD13 in Rheumatoid Arthritis and Inflammatory Arthritis Mouse Model
Chenyang Lu ¹, Phillip Campbell ¹, Jonatan Hervoso ², Stephanie Rasmussen ², Wenyi Fu ², Jeffrey Ruth ², David Fox ³ and M Amin⁴, ¹the University of Michigan, Ann Arbor, MI, ²the University of Michigan, Ann Arbor, ³University of Michigan, Ann Arbor, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory disorder characterized by synovial hyperplasia, inflammatory cell infiltration and pannus formation. We have shown that soluble CD13 (sCD13)…
Abstract Number: 16 • 2019 ACR/ARP Annual Meeting
Monoclonal ACPA Promote Synovial Fibroblasts Migration Through a Peptidylarginine Deiminases (PAD) Dependent Pathway
Meng Sun¹, Bence Rethi ¹, Akilan Krishnamurthy ², Vijay Joshua ³, Alexandra Circiumaru ¹, Aase Hensvold ¹, Marianne Engström ⁴, Sergiu-Bogdan Catrina ⁵, Johanna Steen ⁶, Vivianne Malmström ³, Caroline Grönwall ³, Lars Klareskog ⁷, Heidi Wähämaa ¹ and Anca Catrina ⁷, ¹Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, ²Rheumatology unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Solna, Stockholm, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁴Karolinska Institutet and Karolinska University Hospital, Stockholm, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Stockholm University, Stockholm, ⁷Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) play an important role in rheumatoid arthritis (RA) pathogenesis. ACPAs have different amino acid motif recognition patterns and show cross-reactivity…
Abstract Number: 104 • 2019 ACR/ARP Annual Meeting
Novel, Selective, Orally Active PAD4 Inhibitors for the Treatment of Autoimmune Disorders
Santosh Vishwakarma¹, Gurulingappa Hallur ¹, Himanshu Agrawal ¹, Sharad Singh ¹, Annasaheb Kalange ¹, Seema Chikkur Gangadhar ¹, Shuvranshu PraharaJ ¹, Nafees Ahmad Quresh ¹, Srikanth Kanagal Gopinath ¹, Krishnakumar V ¹, Sameer Mahmood ¹, Rudresh G ¹, Mohd Zainuddin ¹, Rajendra Kristam ¹, Ishtiyaque Ahmad ¹, Ramachandraiah Gosu ¹, Purra Buchi Reddy ¹, N V S K Rao ¹, Saloni Mehra ², Jeyaraj D A ¹, Takeshi Yura ¹, Saravanakumar dhakshinamoorthy ¹, Sriram Rajagopal ¹, Dhanalakshmi Sivanandhan ³ and Sridharan Rajagopal ³, ¹Jubilant Biosys, Bangalore, India, ²Jubilant Chemsys, Noida, India, ³Jubilant Therapeutics, Bangalore, India
Background/Purpose: Citrullination of proteins is catalyzed by a family of enzymes called the peptidylarginine deiminases (PADs). While the citrullinated proteins may have physiological roles in differentiation,…
Abstract Number: 193 • 2019 ACR/ARP Annual Meeting
Diet as a Risk Factor for Rheumatoid Arthritis
Chelsea Guan ¹ and Shazia Beg², ¹University of Central Florida, Orlando, ²University of Central Florida College of Medicine, Orlando
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease affecting the joints that typically affects women more than men. An exact cause has yet…
Abstract Number: 284 • 2019 ACR/ARP Annual Meeting
Impact of Body Mass Index on the Agreement Between Ultrasound- and Clinical Assessments of Disease Activity in Rheumatoid Arthritis : Multicenter and Cross-sectional Study
Gaël Mouterde¹, Federico Manna ², Benoît Le Goff ³, Jean-David Albert ⁴, Sandrine Jousse-Joulin ⁵, Frédérique Gandjbakhch ⁶, Damien Loeuille ⁷, Philippe Gaudin ⁸, Muriel Piperno ⁹, Frédéric Banal ¹⁰, Bénédicte Jamard ¹¹, Carine Salliot ¹², Nicolas Molinari ², Bernard Combe ¹³, Maria-Antonietta D'Agostino ¹⁴ and Cédric Lukas ¹⁵, ¹CHU Montpellier and Univ Montpellier, Montpellier, France, ²Clinical Research and Epidemiology Unit, University Hospital, Montpellier, France, ³Rheumatology Department, CHU de Nantes and INSERM UMR 1238, Faculty of Biology of Nantes, Nantes, France, ⁴Rheumatology department, Rennes University Hospital and Institut NUMECAN, INSERM U 1241, Rennes, Bretagne, France, ⁵Rheumatology Department, Cavale Blanche Hospital and Brest Occidentale University, Brest, France, ⁶Rheumatology department, Pitié Salpêtrière hospital, APHP and Sorbonne University, Paris, France, ⁷Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France, ⁸Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, ⁹Rheumatology Department, Hospices Civils de Lyon, centre hospitalier Lyon Sud, Pierre Bénite, France, ¹⁰Service rhumatologie, hôpital d'instruction des armées Bégin, Saint Mandé, France, ¹¹Department of Rheumatology, Purpan Teaching Hospital, Toulouse, France, ¹²Rheumatology Unit, centre hospitalier regional d'Orleans, Orléans, France, ¹³CHU Montpellier, Montpellier University, Montpellier, France, ¹⁴UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne Billancourt, France, ¹⁵Rheumatology department, CHU Montpellier, Univ Montpellier, Montpellier, France
Background/Purpose: Clinical evaluation of synovitis in rheumatoid arthritis (RA) is difficult in obese (O) and overweight patients, due to the fat pad located around the…
Abstract Number: 449 • 2019 ACR/ARP Annual Meeting
The Course of Disability Related to Function of the Upper Extremities in Early Rheumatoid Arthritis over 10 Years of Follow-up
Maria Rydholm ¹, Ingegerd Wikström ², Maria Mellblom Bengtsson ¹, Sofia Hagel ³, Lennart Jacobsson ⁴ and Carl Turesson², ¹Skåne University Hospital, Malmö, Sweden, ²Lund University, Malmö, Sweden, ³Skåne University Hospital, Lund, Sweden, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased disability, in particular due to involvement of the joints of the upper extremities. The Stanford Health Assessment…
Abstract Number: 476 • 2019 ACR/ARP Annual Meeting
Decreased Muscle Mass, a Novel Predicting Indicator for One-year Radiographic Progression in Rheumatoid Arthritis: A Real-world Cohort Study
Jian-Zi Lin ¹, Jian-Da Ma ¹, Qian-Hua Li ¹, Ying-Qian Mo ¹, Li-Juan Yang ¹, Le-Feng Chen ¹, Chu-Tao Chen ¹, Jun-Wei Wang ¹, Dong-Hui Zheng ¹ and Lie Dai¹, ¹Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China (People's Republic)
Background/Purpose: Obesity paradox based on body mass index (BMI) in rheumatoid arthritis (RA) remain elusive. Our previous cross-sectional study has reported myopenia is associated with joint…
Abstract Number: 526 • 2019 ACR/ARP Annual Meeting
Factors Influencing Discontinuation in Long-term RA Treatment
Madison Grinnell¹, Sofia Pedro ² and Kaleb Michaud ³, ¹University of Nebraska College of Medicine, OMAHA, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While medication persistence can act as a substitute metric for effectiveness, few studies have examined real-world patterns of bDMARD persistence by line of treatment…
Abstract Number: 823 • 2019 ACR/ARP Annual Meeting
The Risk of Venous Thromboembolism in Patients with Psoriatic Disease and Rheumatoid Arthritis, a Population-based Study
Lingyi Li¹, Na Lu ¹, Eric Sayre ¹, Hui Xie ², Diane Lacaille ³, John Esdaile ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Venous thromboembolism (VTE, which includes pulmonary embolism [PE] and deep vein thrombosis [DVT]) is associated with increased morbidity and mortality. Previous studies have shown…
Abstract Number: 930 • 2019 ACR/ARP Annual Meeting
Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator
Norman Gaylis¹, David Sikes ², Alan Kivitz ³, Diane Horowitz ⁴, Charles Peterfy ⁵, Yaakov Levine ⁶, David Chernoff ⁶ and Mark Genovese ⁷, ¹Arthritis and Rheumatic Disease Specialties, Aventura, FL, ²Florida Medical Clinic, Land O Lakes, FL, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Northwell Health, Manhasset, NY, ⁵Spire Sciences Inc, Boca Raton, ⁶SetPoint Medical, Valencia, CA, ⁷Stanford University, Stanford, CA
Background/Purpose: The inflammatory reflex is an endogenous neuroimmune circuit that helps regulate innate and adaptive immunity (Annu. Rev. Immunol. 2012; 30:313). Activation of this reflex by…
Abstract Number: 1140 • 2019 ACR/ARP Annual Meeting
The Socioeconomic, Gender, Urban-rural, and Regional Disparities in the Risk of Acute Myocardial Infarction Among RA Patients
Yufei Zheng¹, Hui Xie ², J. Antonio Avina-Zubieta ³, Kia Yazdani ⁴, John Esdaile ⁵ and Diane Lacaille ⁶, ¹Arthritis Research Canada, Richmond, BC, Canada, ²Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada and the University of British Columbia, Richmond, ⁵Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁶Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: To assess socioeconomic (SES), gender, urban-rural, and regional disparities in the risk of acute myocardial infarction (MI) among rheumatoid arthritis patients.Methods: We conducted a…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].